Lilly to present new long-term extension data on Alzheimer’s drug Kisunla at AAIC 2026

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly flagged upcoming AAIC 2026 presentations that include new trial analyses for Kisunla (donanemab-azbt) in early symptomatic Alzheimer’s disease.
  • Data to be shown July 15 includes TRAILBLAZER-ALZ 2 long-term extension results on biomarkers and potential durability of clinical benefit.
  • Additional analyses focus on safety strategies, including modified titration and corticosteroid pretreatment.
  • Lilly also plans to present P-tau217 blood test results showing rule-in performance comparable to amyloid PET in cognitively unimpaired individuals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607090730PR_NEWS_USPR_____DE00398) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.